MabCure, Inc. Generates Tumor Specific Antibodies against Prostate Cancer Which Could Lead to a Blood/Urine Diagnostic Test for Prostate Cancer

NEW YORK--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) today announced that it has generated a panel of 10 novel monoclonal antibodies (MAbs) against prostate cancer. These MAbs were selected from more than 30,000 MAbs produced by MabCure’s proprietary technology.

Back to news